Cadila Healthcare hits 52-week high on USFDA nod for Clonidine Hcl Injection

Subscribe to GoodReturns

Cadila Healthcare hits 52-week high on USFDA nod for Clonidine Hcl Injection
Shares of drug maker Cadila Healthcare rose nearly 3 per cent, hitting 52-week high, in early trade on Bombay Stock Exchange (BSE) after company announced that it has received the US FDA approval to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.

"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a filing to Bombay Stock Exchange.

Buoyed by development, shares of company gained as much as 2.70 per cent and touched 52-week high to trade at Rs 1022.00 a piece on the BSE.In a similar fashion, shares of the company advanced 1.85 per cent to Rs 1,014.80 a piece on National Stock Exchange.

Meanwhile, the broader benchmark Sensex was quoting at 20,890.91, up 79.47 points or 0.38 per cent at 10:00 hours.

Dion Global Solutions Ltd.

Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Find IFSC